The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study

BACKGROUND: We hypothesized that pretreatment serum levels of insulin and other serum markers would predict Progression-free survival (PFS), defined as time to castration-resistant progression or death, in metastatic androgen-dependent prostate cancer (mADPC). METHODS: Serum samples from treatment-n...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Cancer
Hlavní autoři: Dayyani, Farshid, Zurita, Amado J., Nogueras-González, Graciela M., Slack, Rebecca, Millikan, Randall E., Araujo, John C., Gallick, Gary E., Logothetis, Christopher J., Corn, Paul G.
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2016
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5013640/
https://ncbi.nlm.nih.gov/pubmed/27599544
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2723-1
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky